Employees: 80,129

Employees: 82,089
Change: 1,960, 2.4%

Revenues: 42.531B Swiss francs (approx. $45.214B)

Revenues: 45.5B Swiss francs (approx. $47.8B)

Roche ($RHHBY) is one of the smaller companies in terms of number of employees, ranking eighth, but was fourth last year when ranked by revenue. Roche actually added employees last year, nearly 2,000. It was one of only four in the top 10 that did. But it also grew revenue last year, one of only four to accomplish that as well.  

To a large degree, Roche's accomplishments are a product of its focus on personalized medicine, and more specifically on oncology. More than 60% of its revenue came from cancer drugs, and that does not count the portion of its diagnostics business tied to oncology. And many of those drugs are among the top sellers, even at premium prices. Drugs like Rituxan/MabThera, which earned more than $7 billion, and Herceptin, which sold more than $6.3 billion, go a long way to explaining Roche's place in the lineup.

Employee levels can change significantly with a single acquisition, and Roche's CFO Alan Hippe has said Roche is scouting for deals and would pay up to $7 billion if it found something it really liked.

For more:
CFO: No stock buybacks for Roche. Let's make a $7B deal instead


Suggested Articles

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

J&J chief Alex Gorsky has assured plenty of critics that its talc products are safe, but he's not interested in explaining to Congress.